We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Currently, the self-employed have fewer admissions to financial services than their employed counterparts do. Hatch aims to give sole traders free-to-use access to real-time credit scores that will allow lenders to make more informed decisions when invoice funding. The company also offers digitising of tax files, one of the most time-consuming admin burdens. Revenue is generated via affiliate fees to those who wish to introduce and facilitate Hatch on their platforms. A beta for 5k users will be launching soon, with half the slots already filled.
days to go: Expired investment: £115,000
Cyclr is a cloud-based software that allows the user to connect the apps that they already run their business on. This makes it simple to synchronise data with another system.
days to go: Expired investment: £100,490
A fully integrated, end to end platform that enables real time situation and work force management, for the private security industry.  It ensures regulatory compliance and real time reporting for security operatives.  FalconDHQ is addressing a gap in the market to modernise the current paper based process.        
days to go: Expired investment: £415,000
VINEX is a digital Business-To-Business (B2B) trading platform that connects buyers and sellers to source, sample, negotiate and execute contracts related to wine. The company has traded more than 115 million bottles of wine across 26 countries since 2016. It has also witnessed 3,200 monthly visitors on its platform with an average of 80 million litres of wine traded each month, from 16 countries. The company recently launched VINPay, an industry-first financial technology service customised for the wine industry, providing wineries with guaranteed payment and increased access to capital liquidity. VINEX argues that VINPay pays wineries in 3 days from dispatch, rather than them waiting for 90+ days, and removes non-payment risk. The company points out that it has already started processing invoices, making and receiving payments from 7 countries. VINEX aims to become a contender in the wholesale wine market that is set to exceed US$381 billion in 2021. It will use the investment to help wineries invest and flourish.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £159,720
MyT is a cloud-powered subscription-based accounting software designed for small businesses that allows them to submit financial information to Her Majesty's Revenue and Customs (HMRC) under the Making Tax Digital initiative, which is mandatory from April 2023. MyT asserts that its app provides businesses with a simple way to keep track of business finances on the go, send and manage invoices and bills, and record expenses and mileage. The company claims that its app is available on App Store and Google Play and has witnessed 1000+ downloads to date. It claims that it has onboarded over 500 users without any extensive marketing spend. MyT will use half of the investment to implement its marketing plan, a third for developing new technology and the remaining for administrative expenses.

Pitch Rated

73%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £133,543
aylo's goal is to expedite the shift toward a circular economy. With £22 million in annual recurring revenue, backing from venture capital, and certification as a B Corp, their technology platform facilitates the leasing and reusing of consumer products, making sustainability more accessible and affordable. Raylo recognizes that consumers and retailers will embrace this transition if it's both cost-effective and straightforward.
days to go: Expired investment: £1,282,150
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph